Skip to content
Business Finance

Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development

Caidya 3 mins read
RALEIGH, N.C.--BUSINESS WIRE--

Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/

Michael Clay, Caidya's Chief Operating Officer

Michael Clay, Caidya's Chief Operating Officer

Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust.

Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration are critical to success. His hands-on approach to site partnerships and regional execution aligns closely with Caidya’s distinct global footprint and its strong presence in China — an increasingly vital region for innovative biotech development and patient access.

Most recently, Clay served as senior vice president, Global Project Delivery at Fortrea, where he oversaw more than 500 global clinical trials. His career includes positions as COO and senior operations roles at other global CROs and site management organizations. His expertise in aligning sponsors, sites, and cross-functional teams will further enable Caidya to deliver integrated, agile solutions tailored to the evolving needs of biotech innovators.

“Mike’s leadership strengthens one of our most important differentiators — our ability to combine global reach with regional expertise, particularly across APAC and China,” said Barbara Lopez Kunz, CEO, Caidya. “His deep understanding of site engagement, global execution, and sponsor partnership will help us scale while preserving the agility, accountability, and transparency our clients value.”

“I’m excited to join Caidya at a time when global clinical development is becoming more interconnected and more complex,” said Clay. “Caidya is strategically positioned to help sponsors accelerate programs while maintaining quality and patient focus.”

Clay’s appointment supports Caidya’s continued evolution as a globally integrated, mid-sized CRO that delivers partner-level collaboration rather than transactional execution. Caidya’s distinct APAC infrastructure and experienced regional leadership provide sponsors with a differentiated pathway to access diverse patient populations and execute complex, multi-regional trials with confidence.

This hire continues Caidya’s commitment to grow and strengthen its global team of operational, therapeutic, and commercial leaders. Recent additions include oncology and hematology SME, Edward Dow, M.D.; head of BD Europe, Mario Bautista; and several new commercial executives across the U.S. averaging over 20 years’ life science experience.

About Caidya

Caidya is a global, clinical research organization (CRO) that partners with biopharma innovators to advance breakthrough therapies for patients with unmet medical needs. Built to adapt at the speed of science, Caidya operates as a product development partner, integrating seamlessly with sponsors, bringing ownership, transparency, and agility to complex clinical programs.

With direct presence in more than 20 countries and conducting studies across over 50 countries and regions Caidya offers a distinct global footprint across the Americas, Europe, and APAC, including deep capabilities in China. This cross-border strength enables sponsors to access diverse patient populations, navigate regional regulatory pathways, and execute global trials with confidence. Caidya’s specialized therapeutic and operational expertise spans oncology and hematology, rare and pediatric diseases, and other complex indications where scientific precision and patient-centric execution are critical. By combining global scale with mid-sized agility, Caidya delivers high-quality data, accelerated timelines, and a superior partnership experience from early development through post-approval.


Contact details:

Roger Boutin
VP, Corporate Marketing, Caidya
[email protected]

Janice Foley
Sr Dir PR & Media, SCORR Marketing
[email protected]
+1 (308) 338-2358

Media

More from this category

  • Business Finance
  • 13/03/2026
  • 00:41
Andersen Consulting

Andersen Consulting Broadens Capabilities Through Collaboration with Acumen Learning

SAN FRANCISCO--BUSINESS WIRE-- Andersen Consulting adds depth to its platform through a Collaboration Agreement with Acumen Learning, a U.S.-based firm specializing in business and financial acumen training for leadership development and sales performance. Founded in 2002, Acumen Learning works with Fortune 500 companies to enhance financial literacy, strategic thinking, and decision-making across all levels. Drawing from the principles in their best-selling books “Seeing the Big Picture” and “Business Acumen for Sales Success,” their programs equip leaders and teams to align decisions with corporate strategy, drive performance, and strengthen client relationships. Tailored for industries such as healthcare, energy, and technology, Acumen…

  • Business Finance
  • 12/03/2026
  • 19:11
Egon Zehnder

Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth

ZURICH & LAUSANNE, Switzerland–BUSINESS WIRE– Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global…

  • Contains:
  • Business Finance
  • 12/03/2026
  • 00:41
Andersen Consulting

Andersen Consulting Strengthens Platform with Collaborating Firm Ambit Iberia

SAN FRANCISCO--BUSINESS WIRE-- Andersen Consulting expands its technology and business transformation capabilities through a Collaboration Agreement with Ambit Iberia, a consulting firm specializing in digital and regulatory solutions for the life sciences sector. Founded in 2003 and headquartered in Spain, Ambit Iberia provides integrated consulting, technology, and talent solutions for pharmaceutical, biotechnology, and medical device companies. The firm supports clients in meeting evolving quality, compliance, and regulatory standards through services spanning regulatory affairs, data integrity, IT system validation, and digital transformation. Leveraging more than 20 years of industry expertise, Ambit Iberia also offers human capital and executive search services that…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.